Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass? Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

AbstractObjective: Evaluation of the hemostatic and plateletseffects in children with acyanogenic congenital heart diseaseundergone on-pump surgery who received aprotinin. Methods: A prospective randomized study was performedon children aged 30 days to 4 years who had undergonecorrection of acyanogenic congenital heart disease usingcardiopulmonary bypass (CPB) and were divided into twogroups: Control (n=9) and Aprotinin (n=10). In the AprotininGroup the drug was administered before and during CPBand the hemostatic dysfunction was analyzed by clinicaland biochemical markers. Differences were considered tobe significant when P <0.05. Results: The groups were similar regarding demographicand intraoperative variables, except for a greaterhemodilution in the Aprotinin Group. The drug presentedno benefit regarding time of mechanical pulmonaryventilation, stay in the postoperative intensive care unitand hospital, or regarding the use of inotropic drugs andrenal function. Platelet concentration was preserved withthe use of Aprotinin, whereas thrombocytopenia occurredin the Control Group since the initiation of CPB. Blood losswas similar for both groups. There were no complicationswith the use of Aprotinin.